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ELABELA (ELA) is a peptide hormone required for
heart development that signals via the Apelin Recep-
tor (APLNR, APJ). ELA is also abundantly secreted
by human embryonic stem cells (hESCs), which do
not express APLNR. Here we show that ELA signals
in a paracrine fashion in hESCs to maintain self-
renewal. ELA inhibition by CRISPR/Cas9-mediated
deletion, shRNA, or neutralizing antibodies causes
reduced hESC growth, cell death, and loss of plurip-
otency. Global phosphoproteomic and transcrip-
tomic analyses of ELA-pulsed hESCs show that
it activates PI3K/AKT/mTORC1 signaling required
for cell survival. ELA promotes hESC cell-cycle pro-
gression and protein translation and blocks stress-
induced apoptosis. INSULIN and ELA have partially
overlapping functions in hESC medium, but only
ELA can potentiate the TGFb pathway to prime
hESCs toward the endoderm lineage. We propose
that ELA, acting through an alternate cell-surface re-
ceptor, is an endogenous secreted growth factor in
human embryos and hESCs that promotes growth
and pluripotency.
INTRODUCTION
Human pluripotent embryonic stem cells (hESCs) represent
a particular spatiotemporal state of human embryogenesis, i.e.,
the peri-implantation epiblast (Brons et al., 2007; Tesar et al.,
2007). As such their study allows us to understand the cues
and requirements that drive and regulate the earliest events of
human development. Because of this biological significance
and their clinical relevance for regenerative medicine, a great
emphasis has been placed on elucidating the mechanisms un-
derlying the ‘‘pluripotent circuitry network,’’ which is composed
mainly of transcription factors, chromatin regulatory proteins,
and signaling pathways activated by extracellular growth factors
(Warmflash et al., 2012). In particular, hESCs require a finely-
tuned cocktail of exogenous basic FIBROBLAST GROWTHCeFACTOR (bFGF), NODAL/ACTIVIN, and INSULIN/INSULIN-
LIKE GROWTH FACTORs (IGFs) for continued self-renewal (Val-
lier et al., 2005; Voskas et al., 2014; Xu et al., 2005). Aside from
these, no other secreted factors have been isolated from hESCs
or feeder-conditioned medium and proven to be necessary for
maintaining self-renewal.
While examining the pluripotency gene signature of hESCs, we
discovered a gene NM_001297550 that encodes an evolution-
arily conserved 54-amino acid hormone named ELABELA (also
known as APELA) (http://www.elabela.com). We and others
have found that Ela signals through the Apelin Receptor (Aplnr,
also known as Apj) to mediate endoderm differentiation during
zebrafish embryogenesis (Chng et al., 2013; Pauli et al., 2014).
In humans, ELA expression during development is highest in
the blastocyst (Hs. 105196, LOC100506013) and is rapidly down-
regulated during hESC differentiation (Miura et al., 2004). To our
knowledge, no hormonal peptide has ever been implicated in
maintaining the self-renewal capacity of hESCs or their ability
to differentiate into the three embryonic germ layers. Recently,
murine Ela was reported to also function as a long non-coding
RNA that promotesDNA-damage-induced apoptosis (DIA)medi-
ated by p53 via sequestration of the p53 inhibitor, hnRNPL (Li
et al., 2015). Intriguingly, this functionwas shown to be entirely in-
dependent of the translated Ela peptide or its cognate receptor
Aplnr. Here, we demonstrate that in hESCs, ELA is a bona fide
endogenous ligand necessary for maintaining growth and self-
renewal. Through phospho-proteomic analysis, we find that
ELA is necessary and sufficient to activate the Phosphatidylinosi-
tol-4,5-bisphosphate 3-kinase (PI3K)/AKT pathway to potentiate
hESCgrowth andprotect against cellular stress.While ELAcan in
part replace the need for exogenous INSULIN, the two are func-
tionally distinct and non-redundant. Consistent with its role in
promoting endoderm development in the zebrafish, ELA, unlike
INSULIN, is required to poise hESCs toward the mesendoderm
lineage, pointing to a dual function in maintaining the self-renew-
ing state and facilitating early lineage commitment.
RESULTS
ELA Is a Conserved Hormone Associated with Human
Embryonic Pluripotency
Within the human pluripotency circuitry network, which we
delineated as the core intersection of the NANOG, POU5F1ll Stem Cell 17, 435–447, October 1, 2015 ª2015 Elsevier Inc. 435
Figure 1. ELA Is Associated with Human
Embryonic Stemness
(A) NANOG, POU5F1, and PRDM14 syn-expres-
sion groups define a common list of 33 transcripts
which are at the core of the human pluripotency
circuitry. ELA is one of these genes.
(B) Luciferase reporter assay demonstrating that
ELA is under direct transcriptional control by an
upstream POU5F1 enhancer.
(C) ELA mRNA levels were measured by qPCR in
control and POU5F1-knockdown hESCs.
(D) ELA mRNA expression in undifferentiated
hESCs and during embroid body differentiation.
Left axis: ELA and POU5F1; right axis: PAX6,
SOX17, and NKX2.5, expressed as percentages
relative to Day 0.
(E) Secreted ELA is detected in the supernatant of
hESCs by ELISA. shRNA-mediated stable knock-
down of ELA (shELA) reduces levels of secreted
ELA by approximately 85%.
(F) Inducible CRISPR/Cas9 vector for derivation of
ELAiCRISPR and AAVS1iCRISPR hESCs.
(G) FACS analysis of ELAiCRISPR and AAVS1iCRISPR
hESCs serially passaged in the presence of DOX to
track the persistence of GFP-positive genome-
edited cells over four passages (P0 to P3).
(H) The percentage of GFP-positive ELAiCRISPR
hESCs rapidly declines over four passages com-
pared to GFP-positive AAVS1iCRISPR hESCs. Data
are represented by the mean of six wells ± SEM.
(I) Immunofluorescence of ELA in control and
shELA hESCs.
See also Figure S1.(also known as OCT4), and PRDM14 syn-expression groups
(Day et al., 2009; Niehrs and Pollet, 1999), lies a list of 33
transcripts (Figure 1A and Table S1), 6 of which are still un-
known or uncharacterized. One, ELABELA (ELA), was previ-
ously reported to be specific to undifferentiated hESCs (Chng
et al., 2013; Miura et al., 2004). According to UniGene, the
Hs. 105196 transcript is highly and specifically expressed in hu-
man blastocysts before implantation (Figures S1A and S1B;
UGID: 143461). Its expression in hESCs is dependent on an
active POU5F1 regulatory element lying 10 kb upstream of its
promoter and is contingent on endogenous POU5F1 activity
(Figures 1B and 1C). Consistent with this, ELA transcription
is highest in undifferentiated hESCs and becomes rapidly
silenced during embryoid body (Figure 1D), endodermal, and
neuronal differentiation (Figures S1C and S1D). These data vali-
date that ELA expression is correlated with the undifferentiated
state of hESCs and is associated with pre-implantation human
development.
ELA Is Secreted by hESCs and Is Required for
Self-Renewal
ELA is translated into a bona fide protein that is readily detected
in hESCs and in human embryonal carcinoma cells (ECs) by
immunofluorescence using two custom ELA antibodies that
recognize either the N or C terminus (Figures 1I and S1E) of the
mature ELA peptide. ELA co-localizes with TGN46, a marker
of the trans-Golgi network (Chng et al., 2013). We confirmed
that endogenous ELA is indeed secreted because it is readily436 Cell Stem Cell 17, 435–447, October 1, 2015 ª2015 Elsevier Inc.detected in the supernatant of cultured hESCs using a custom
sandwich ELISA assay (Figure 1E). We estimated that over a
period of 5 days, ELA reaches low nanomolar concentrations
in the supernatant of hESCs (Figure 1E).
To assess the function of ELA in hESCs, we first attempted to
generate hESC clones with homozygous genetic deletion of ELA
using CRISPR/Cas9 technology (Cong et al., 2013; Jinek et al.,
2012; Mali et al., 2013). To circumvent the appearance of
culture-adapted hESC clones imposed by strong selective
pressures (Avery et al., 2013), we devised an inducible CRISPR
platform in which Cas9 expression is under doxycycline (DOX)
control (Figure 1F). Coexpression of Cas9 and gRNAs targeting
exon 1 of ELA (referred to as ELAiCRISPR) or the AAVS1 intronic
locus resulted in similar mutation frequencies (primarily frame-
shifts in the ELA locus) as measured by droplet digital PCR
(ddPCR) (Figure S1F). This method infers mutation frequency
by measuring reduction in wild-type genomic DNA copy number
as a result of Cas9 editting. Following dissociation and growth at
clonal density, we were only able to recover 25.5% and 5.5%
with mono- and bi-allelic mutations, respectively (Figures S1G
and S1H). This represents a statistically significant reduction in
the observed number of clonal outgrowths with mutations in
ELA compared to the expected rate (c2 = 0.0008), pointing to a
severe growth disadvantage of ELA-het or ELA-null hESCs.
Indeed, serial passaging of GFP-positive ELAiCRISPR hESCs
in the presence of DOX (such that the ELA locus is continu-
ously edited) resulted in the rapid demise and concomitant
differentiation of GFP-positive ELAiCRISPR hESCs compared to
Figure 2. ELA Is Necessary and Sufficient
for hESC Growth and Viability
(A) Cell index measurements (xCELLigence) of
shELA and shb2M (inset) hESCs seeded as single
cells over 5 days. Cell Index is an approximation of
cell numbers.
(B) FACS analysis of SSEA3 and TRA-1-60 3 days
after induction of shRNA by DOX.
(C) Immunofluorescence for SSEA3, POU5F1, and
TRA-1-60 in control and shELA hESC colonies af-
ter four passages of knockdown.
(D) Control and shELA hESCs were injected sub-
cutaneously into NOD-SCID-GAMMA mice. Tera-
toma formation was visualized after 1 month.
(E) ELA and mutant ELARR > GG (R31G, R32G),
with an intramolecular cystine bond between
conserved C39 and C44 residues, were syntheti-
cally produced to 98% purity.
(F) By immunofluorescence, recombinant ELA,
but not ELARR > GG, labeled with N-terminal FITC is
rapidly taken up by hESCs.
(G) Brightfield images of shRNA hESCs and
wild-type hESCs cultured with exogenous ELA or
ELARR > GG after 4 days of shRNA or peptide
treatment.
(H) Real-time cell index measurements of hESCs
cultured with exogenous ELA or ELARR > GG over
4 days.
(I) Real-time cell index measurements over 5 days
of shELA hESCs rescued with exogenous ELA, but
not ELARR > GG.
(J) hESCs were cultured with affinity purified a C
antibody, which inhibited their growth. This
neutralizing activity can be outcompeted by the
mutant non-signaling ELARR > GG peptide which
competes for the a C antibody.
(K) Real time cell index measurements of multi-
potent human embryonal carcinoma cells (ECs) or
unipotent human chondrosarcoma and primary
fibroblast cells cultured with exogenous ELA over
5 days, with no apparent effect.
(L) H1, H9, and SHEF4 hESC lines were grown with
exogenous ELA or a C antibody. Cell numbers
were measured after 4 days. Data are represented
by the mean of six wells ± SEM.
See also Figure S2.contaminating CRISPR/Cas9/GFP-negative cells, indicating a
selective disadvantage of ELA-null hESCs in culture over
wild-type non-edited hESCs (Figures 1G and S1J). In contrast,
this effect was not observed in GFP-positive AAVS1iCRISPR or
GFP-positive hESCs lacking a gRNA (Figures 1G and 1H and
S1)I–S1J.
In order to circumvent thedifficulty of obtainingELA-null hESCs
without the artificial selective pressure of culture adaptation, we
chose instead to knock down ELA and a control non-essential
gene, b2-MICROGLOBULIN (b2M) (Figure S2A), using stable
DOX-inducible shRNA (Zafarana et al., 2009). shELA knockdown
achieved approximately 85% depletion of ELAmRNA and extra-
cellular ELA relative to control levels (Figures 1E and S2A). The in-
tensity of ELA staining was also markedly reduced upon siRNA-
and shRNA-mediated ELA knockdown (Figures 1I and S2B).
shELA hESCs displayed significantly reduced growth rates com-
pared to control or shb2M hESCs when seeded as single cells as
shown by real-time cell index analysis on the xCELLigence plat-Ceform (Figure 2A). Slower growth rates were also documented in
shELA hESC colonies that were on average less than half the
size of shb2M hESCs (Figure S2C). After 3 days of knockdown,
shELA hESCs showed reduced surface levels of pluripotency
markers SSEA3 and TRA-1-60 (Figure 2B). Over the course of
four passages in both single-cell and colony format, depletion of
ELA, but not b2M, resulted in a loss of hESC colony morphology
and pluripotency markers POU5F1, NANOG, SSEA3, and TRA-
1-60 (Figures 2C, S2D, and S2E). In line with these results and in
contrast to control hESCs, shELA hESCs injected into NOD-
SCID-GAMMA mice did not form teratomas (Figure 2D). All
together, these findings argue that the endogenous peptide ELA
is key to hESC self-renewal.
Exogenous ELA Is Sufficient to Promote Growth of
hESCs
We next assessed the bioactivity of mature ELA. To this end
we synthetically produced ELA at 98% purity as a 32-aminoll Stem Cell 17, 435–447, October 1, 2015 ª2015 Elsevier Inc. 437
Figure 3. APLNR Is Not the ELA Receptor in
hESCs
(A) FACS analysis of surface-expressed APLNR in
undifferentiated (Day 0) versus Day 3 hESC-derived
mesoendoderm (Day 3).
(B) AP-ELA binding assay on a variety of hESCs
and also differentiated human cell lines. Data
represent intensity of colorimetric readout and are
means of three wells ± SEM.
(C) AP-ELA binding assay on shControl and
shAPLNR undifferentiated hESCs (Day 0) versus
Day 3 hESC-derived mesoendoderm (Day 3).
(D) Mutation of the indicated residues to glycine
affects binding of AP-ELA to SHEF4 and HES3
hESCs. Input supernatants were normalized by
their AP activity to ensure that equal amounts of
each AP-ELA mutant were used for binding.
(E) Biotinylated ELA peptide applied to hESCs
was detected using streptavidin with or without
prior permeabilization of the cell surfacemembrane
by digitonin.
(F) FITC-labeled ELA was bound to hESCs with
or without a 5 min pretreatment of cells with a
low concentration of trypsin, followed by FACs
analysis.
(G) FITC-labeled ELA was bound to hESCs in
the presence or absence of methyl-b-cyclodextrin
(MbCD) or Chlopromazine, followed by FACs
analysis.
See also Figure S3.acid peptide bearing an intramolecular cysteine bond between
cysteine residues 39 and 44 (Figure 2E). Synthetic FITC-
labeled ELA was readily taken up by hESCs (Figure 2F). We
discovered that mutation of two invariant arginines into gly-
cines (R31G and R32G) completely abolished the uptake of
ELA (Figures 2E and 2F). While shELA hESCs showed reduced
growth, hESCs pulsed with wild-type ELA peptide showed
dose-dependent enhanced growth relative to untreated
hESCs. This was independently documented by cell counts
(Figure S2F), colony size (Figure 2G), and real-time measure-
ment of cell indices (Figures 2H and S2G). The doubly mutated
ELA mutant peptide (referred to as ELARR > GG) had no effect in
these assays (Figures 2E and 2H). Notably, the growth of
shELA hESCs was entirely rescued by the addition of recombi-
nant ELA, but not ELARR > GG, showing that ELA can be pro-
vided exogenously (Figure 2I). We therefore hypothesized
that direct inhibition of ELA in the extracellular space should
yield results similar to its depletion at the transcript or genetic
level. Indeed, we found that addition of antigen affinity-purified
a C and a N antibodies to hESC medium recapitulated the
effects of shELA (Figures 2J and S2H), indicating that these an-
tibodies have potent ELA-neutralizing activity. ELARR > GG pep-
tide was used as a competitive inhibitor to the a C antibody to
prove the specificity of this assay (Figure 2J). Moreover, the
combined use of shELA and a C neutralizing antibodies re-
sulted in an exacerbated loss of growth compared to each in-
hibition alone (Figure S2F).
It is noteworthy that recombinant ELA and a C antibody pro-
moted and inhibited, respectively, only the growth of hESCs
and no other differentiated cell types such as ECs, a human438 Cell Stem Cell 17, 435–447, October 1, 2015 ª2015 Elsevier Inc.chondrosarcoma cell line, or primary human fibroblasts (Fig-
ure 2K). With respect to cell growth, H1, H9, and SHEF4 hESCs
all responded similarly to the loss or gain of function of ELA
(Figure 2L), indicating that ELA is generally required for the hu-
man ‘‘primed’’ pluripotent state. Primed hESCs can be reprog-
rammed by a variety of methods to a more ‘‘naive’’ state
believed to capture an earlier stage of human embryonic devel-
opment (Hanna et al., 2010). We employed the ‘‘3iL’’ method
to derive naive ESCs that resemble preimplantation epiblast
(Chan et al., 2013) and found that ELA expression was un-
changed in the 3iL state compared to the primed state (Fig-
ure S2I). ELA depletion using a C antibodies or shRNA had a
negligible effect on 3iL ESCs, while exogenous ELA had only
a modest, albeit statistically significant, effect on cell growth
(Figures S2J–S2L). All together, these data suggest that ELA
is a specific growth factor of the human primed ESCs (i.e.,
hESCs) and not naive hESCs.
APLNR Is Not the ELA Receptor in hESCs
We and others have shown that ELA serves as a cognate ligand
to the cell surface APLNR to mediate endoderm development
and subsequent heart morphogenesis. However, in agreement
with previous reports (Vodyanik et al., 2010; Yu et al., 2012),
APLNR is absent in undifferentiated hESCs. Unlike ELA, which
is marked by H3K4me3 and actively transcribed, the APLNR
locus is methylated and not transcribed in hESCs (Figure S3A).
We confirmed the absence of APLNR transcripts in both
SHEF4 and HES3 hESC lines by qPCR and flow cytometry
(Figure 3A). In contrast, APLNR transcripts were upregulated
nearly 2,500-fold upon mesendoderm differentiation, when
cell surface APLNR became robustly detectable (Figures 3A
and S3B). Nonetheless, we performed shRNA-mediated deple-
tion of APLNR in undifferentiated hESCs to ensure that trace
levels of APLNR could not mediate the effects of ELA on hESCs
(Figures S3B and S3C). We adapted our ELA cell surface bind-
ing assay (Chng et al., 2013) to several hESC lines including
induced pluripotent ESCs (hiPSCs) and found that they readily
bound to the Alkaline Phosphatase-ELA (AP-ELA) fusion pro-
tein (Figure 3B), indicating the presence of an endogenous
cell-surface receptor. The level of AP-ELA binding to undiffer-
entiated hESCs was not affected by shAPLNR, whereas
shAPLNR hESC-derived mesendoderm cells had significantly
less binding (Figure 3C). These data suggest that while
APLNR is necessary to confer cell-surface binding to ELA in
mesendoderm cells, it is not the receptor for ELA in undifferen-
tiated hESCs. Consistent with this conclusion, the growth of
shAPLNR hESCs was not compromised (Figure S3D). From
these experiments, we predict that an alternate ELA receptor
exists in hESCs and is responsible for maintaining self-renewal.
We also documented AP-ELA binding to a variety differentiated
cell types such as HEK293T and primary skin fibroblasts and
found that ELA binds only to undifferentiated hESCs (Figure 3B).
This receptor binding activity is impaired or abrogated by mu-
tations in several conserved residues in ELA, namely C44 and
R31R32, demonstrating specificity for this assay. The binding
of ELA to this receptor results in its internalization, since
biotin-labeled ELA can only be detected using streptavidin if
ELA-pulsed hESCs are permeabilized (Figure 3E). Internaliza-
tion of ELA, quantified using flow cytometry, is abrogated by
pre-treatment of hESCs with trypsin (Figure 3F), indicating
that the receptor activity is dependent on a cell-surface protein.
ELA uptake is also impaired by treatment of hESCs with
methyl-b-cyclodextrin (MbCD) but not chlorpromazine (Fig-
ure 3G), two widely used inhibitors of clathrin-independent
and clathrin-dependent endocytosis, respectively (Conner and
Schmid, 2003). Alt together, these results demonstrate that
ELA binds to an alternate (non-APLNR) protein receptor pre-
sent on the surface of human pluripotent cell types and is inter-
nalized upon binding.
ELA Activates the PI3K/AKT Pathway in hESCs
To identify the components of the ELA signal transduction
pathway in hESCs, we used the proteomic approach Stable
Isotope Labeling by Amino acids in Cell culture (SILAC) (Ong
et al., 2002). We analyzed the phosphoproteome of hESCs
pulsed with ELA for 10 min in order to identify immediate tar-
gets, using the inactive ELARR > GG peptide as a baseline con-
trol (Figure 4A). The experiment was performed twice in both
forward and reverse configurations, and only hits that were
replicated were further investigated. We focused our attention
on LNpTSDFQK, which was among the top phosphopeptides
activated by ELA, but not ELARR > GG, and derived from
PRAS40 (proline-rich Akt substrate of 40 kDa, a.k.a AKT1S1)
(Figure 4B). PRAS40 is an immediate downstream substrate
of AKT, which is in turn activated by PI3K (Vander Haar et al.,
2007). This suggests that ELA activates the PI3K/AKT pathway.
Indeed, addition of recombinant ELA to hESCs was sufficient to
trigger the immediate phosphorylation of AKT at serine 473,
leading to phosphorylation of PRAS40 at threonine 246 (Fig-Ceure 4C). This was not observed in cells treated with mutant
ELARR > GG or vehicle control (Figure S3E) and was abrogated
by pre-treating the cells with pan-PI3K inhibitor LY249004 (LY),
but not by shRNA-mediated APLNR depletion (Figures 4D and
4E). This demonstrates that ELA activation of AKT is APLNR in-
dependent and requires PI3K. Once phosphorylated, PRAS40
is inactivated, relieving its repressive effect on the mammalian
target of Rapamycin (mTORC1) complex (Wang et al., 2012).
The subsequent activation of the mTORC1 by ELA is evidenced
by phosphorylation of its prototypical substrate p70S6K (Fig-
ure 4C) (Peterson et al., 1999). Hence, ELA activates the
PI3K/AKT pathway and subsequently the mTORC1 pathway.
PI3K/AKT and mTORC1 are both potent regulators of growth
and viability and contribute integrally to the self-renewal capac-
ity of hESCs (Armstrong et al., 2006; Zhou et al., 2009). Con-
sistent with the loss of self-renewal and viability of shELA
hESCs, we find that shELA hESCs indeed have lower levels
of endogenous PI3K/AKT and mTORC1 activity, which can be
revealed by gradually lowering levels of exogenous INSULIN
in the growth media (Figure 4F). These results suggest that
the growth deficiency seen in shELA hESCs is attributable to
the loss of paracrine and autocrine PI3K/AKT signaling medi-
ated by endogenous ELA.
Murine and human ESCs are known to differ in their require-
ments for exogenous growth factors (Rao, 2004). We next
tested if the requirement for ELA extends to murine pluripotent
stem cells. mESCs express low levels of Ela, and relative to
hESCs, they do not secrete Ela peptide at detectable levels
(Figures S4A and S4B). Although Ela mRNA levels are upregu-
lated during the transition from naive mESCs to epiblast-like
stem cells (Epi-like SCs) (Figure S4A), we found that neither
naive mESCs nor Epi-like SCs are affected by a C-mediated
Ela inhibition or the addition of exogenous ELA (Figures S4C
and S4D). Consistently, Ela does not activate PI3K/AKT and
does not bind to the surface of mESCs, suggesting that Ela
is not functional in these cells (Figures S4E–S4G). These re-
sults are in line with recent findings that in mESCs, Ela func-
tions as a non-coding RNA independently of the translated
Ela peptide to promote p53-mediated apoptosis (Li et al.,
2015).
ELA and INSULIN/IGF Have Overlapping and Distinct
Roles in hESCs
Unlike mESCs, hESCs are dependent on exogenous INSULIN
and endogenous IGF2 (Bendall et al., 2007), both of which acti-
vate the PI3K/AKT pathway to mediate self-renewal and prevent
differentiation (Singh et al., 2012). For this reason,mTSER1 (used
in this study) and most formulations of hESC medium contain
high levels of INSULIN. To investigate the functional interplay
between INSULIN and ELA, we cultured hESCs in a defined
TSERe8 medium (Chen et al., 2011), which only contains four
growth factors, INSULIN, bFGF, TGFb1, and TRANSFERRIN,
to allow precise control over its composition. INSULIN is the
sole activator of AKT in this formulation (Figure S4H). In SHEF4
and HES3 hESCs, we observed a high rate of cell death after
24 hr of growth in the absence of INSULIN. Addition of ELA
rescued cell viability by 80%–90%, while ELARR > GG showed
no effects (Figures S4I and S4J). On the contrary, shELA hESCs
were exquisitely sensitive to INSULIN withdrawal compared toll Stem Cell 17, 435–447, October 1, 2015 ª2015 Elsevier Inc. 439
Figure 4. ELA Is the Endogenous Signal for Activation of PI3K/AKT in hESCs
(A) Schematic of SILAC-based phospho-proteomic analysis to elucidate immediate signal transduction of ELA in hESCs.
(B) Mass spectra of a PRAS40-derived peptide showing phosphorylation on T246 by ELA, but not ELARR > GG, suggesting activation of the AKT pathway.
(C) hESCs were pulsed with ELA and lysed at the indicated time points. Western blots show immediate activation of the PI3K/AKT and mTORC1 pathways.
Lysates for the top and bottom panels were derived from separate technical replicates.
(D) Activation of AKT by ELA is dependent on PI3K and is abrogated by pan-PI3K inhibitor LY294002 (LY).
(E) Activation of AKT by ELA in shAPLNR hESCs is not impaired.
(F)Western blots of pAKT in Control and shELA hESCs grown in decreasing INSULIN concentrations for 24 hr reveal the requirement for ELA-mediated AKT
activation.
(G) By real-time cell index analysis over 5 days, ELA, but not ELARR > GG, can partially rescue the requirement for INSULIN in hESCs growth medium.
See also Figure S4.control hESCs, and addition of ELA provided an intermediate
growth rescue (Figure S4K). ELA partially replaced INSULIN
over 5 days of growth in a PI3K-dependent manner, since addi-440 Cell Stem Cell 17, 435–447, October 1, 2015 ª2015 Elsevier Inc.tion of LY abrogated the rescuing effect of ELA (Figure 4G). How-
ever, ELA cannot entirely replace INSULIN, since hESC cultures
lacking INSULIN eventually display slower growth and decline,
Figure 5. ELA and INSULIN Are Functionally
Distinct
(A) PCA analysis of microarray data using probe-
sets that showed at least greater than 1.5-fold
change (one-way ANOVA, p < 0.05) between at
least one pair of conditions.
(B) Venn diagrams depicting the overlap of probe-
sets changed by more than 1.5-fold in ELA-treated
(representing 42 upregulated and 16 downre-
gulated genes) and INSULIN-treated (1 upregu-
lated and 5 downregulated genes) hESCs.
(C) Self-organizing map of all probesets in the da-
taset with greater than 1.5-fold change between at
least one pair of conditions (one-way ANOVA, p <
0.05). Selected clusters of ELA-dependent genes
are highlighted to depict their variable dependence
on PI3K/AKT activity.
See also Figure S5.even if exogenous ELA is supplied (Figure 4G and data not
shown). The opposite is also true, since ELA depletion cannot
be fully rescued by exogenous INSULIN. This prompted us to
carefully examine the differential downstream effects of ELA
and INSULIN.
To this end, we profiled the global transcriptional response of
hESCs toward ELA or INSULIN 12 hr following stimulation in
the presence and absence of LY in order to delineate PI3K-
dependent gene targets. ELA and INSULIN activated AKT to
an equal extent (Figure S5A). Microarray data were validated
and verified by qPCR using several representative genes (Fig-
ure S5B). Two major themes arise from analysis of these data.
First, principle component analysis (PCA) and hierarchical clus-
tering of the data indicate that ELA and INSULIN-treated
hESCs are distinct and are equally distant from control-treatedCell Stem Cell 17, 435–44hESCs, while LY was very potent and
had major and overriding effects on
gene expression (Figures 5A and S5C).
Although ELA and INSULIN activated
AKT equally, ELA elicited a greater tran-
scriptional response compared to that
of INSULIN, with little overlap in tran-
scriptional targets (Figure 5B). This result
points to the distinct potency and activity
of the two growth factors on hESC gene
expression via the PI3K/AKT pathway.
Second, self-organizing map (SOM) anal-
ysis of ELA-activated genes revealed
variable dependence of ELA activity on
PI3K/AKT activity. ELA-activated genes
can either be sensitive to PI3K inhibition
(PI3K dependent), insensitive to PI3K in-
hibition (PI3K independent), or enhanced
by PI3K inhibition (PI3K repressed) (Fig-
ure 5C). These results demonstrate that
while ELA can activate the PI3K pathway,
its downstream effects are not exclu-
sively mediated through PI3K. In fact, a
part of its activity appears to be antago-
nized and held in check by PI3K. Theseobservations indicate a clear distinction in the nature and activ-
ity of ELA relative to INSULIN, consistent with our observation
that the two growth factors can only partially rescue one
another.
ELA Impacts Cell Cycle and Protein Translation
Downstream of PI3K/AKT
To explore how ELA functions specifically during self-renewal,
we made use of the gene signature discovery tool Gene
Set Enrichment Analysis (GSEA) (Subramanian et al., 2005).
Consistent with activation of the PI3K/AKT pathway, genes in
the mTORC1 signaling pathway were positively enriched or
upregulated by ELA gain-of-function (Figure S5D). Conversely,
microarray analysis of shELA hESCs showed that ELA loss-of-
function led to a statistically significant downregulation of7, October 1, 2015 ª2015 Elsevier Inc. 441
Figure 6. ELA Promotes Translation and Proliferation and Protects against Stress-Induced Apoptosis
(A) GSEA profile plots depicting negative enrichment of ribosomal genes and genes involved in translation in shELA compared to control hESCs. NES, normalized
enrichment score.
(B) Pulse-chase analysis by metabolic labeling to measure the rate of newly synthesized proteins in shControl versus shELA hESCs. Cells were harvested for
FACs analysis of incorporated fluorescent amino acid 15 and 75 min after pulsing.
(C) Metabolic labeling to measure the rate of newly synthesized proteins in Control versus ELA-treated hESCs in the absence (top) or presence (bottom) of
Rapamycin and LY. Cells were harvested for microscopic measurement of label incorporation 15 min after the addition of the amino acid label.
(D) 23 hours following release from a double thymidine block, shELA hESCs show an accumulation of cells in the G1 phase as measured by DNA content.
(E) Cell-cycle analysis using FUCCI-H9 hESCs synchronized by a double thymidine block following treatment with ELA, LY, or both 19 hr post-release.
(legend continued on next page)
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the same mTORC1 gene set (Figure S5D). A key function of
the mTORC1 pathway is to regulate protein translation in
response to growth factors, through the activation of p70S6K
and transcription of ribosomal genes (Workman et al., 2014).
In agreement, GSEA analysis showed a statistically significant
downregulation of genes involved in protein translation and
ribosome biogenesis in shELA hESCs (Figure 6A). Indeed,
shELA hESCs exhibited reduced protein synthesis as assayed
by incorporation of fluorescently labeled methionine (Fig-
ure 6B). Conversely, ELA treatment increased the proportion
of cells with a higher fluorescence intensity following pulsing
with fluorescently labeled methionine (Figure 6C). This effect
was completely reversed by the mTOR inhibitor Rapamycin
or the PI3K inhibitor LY. Hence, ELA promotes the growth of
hESCs through PI3K/mTOR-dependent activation of protein
translation.
A second function of the PI3K/AKT pathway is control of the
cell-cycle progression through the G1/S phase, in part through
post-translational stabilization of CYCLIN D (Muise-Helmer-
icks et al., 1998). Unlike mESCs, in which Cyclin D is mostly
inactive (Stead et al., 2002), the pRB-CYCLIN D/CDK4/6
cascade in hESCs is operational and is indispensable for
G1/S transition and pluripotency (Pauklin and Vallier, 2013).
We hypothesized that the loss of PI3K/AKT signaling in shELA
cells results in an accumulation of cells in the G1 phase. Care-
ful analysis of the cell cycle of shELA hESCs following release
from a double thymidine block (which synchronizes cells at the
beginning of the S phase) revealed a noticeable increase of
cells in G1 (Figure 6D). Exogenous ELA had the opposite effect
(Figure 6D). We confirmed this observation using FUCCI-H9
hESCs, which afford real-time and live observation of cell-cy-
cle progression (Pauklin and Vallier, 2013). Synchronized ELA-
treated hESCs had a statistically significant decrease in the
proportion of cells in the early G1 phase and an increase in
the proportion of cells in the S/G2/M phase (Figures 6E and
6F), suggesting a promotion of G1/S transition. Conversely,
treatment of hESCs with LY lengthened the residence time
in the early G1 phase and reversed the effects of ELA (Figures
6E and 6F). ELA treatment for 48 hr clearly decreased cell
doubling time, resulting in a 2-fold increase in cell numbers
relative to control and LY-treated hESCs (Figure 6G). Con-
sistent with these results, ELA pulsing led to an increase in
CYCLIN D1 (CCND1) protein levels in a PI3K-dependent
manner (Figure 6H). All together, these data indicate that
ELA acts through the PI3K/AKT/mTORC1 pathway in hESCs
to potentiate growth by promoting cell-cycle progression
and optimal protein translation.(F) Quantitation of data in (E) at the indicated time points following thymidine blo
(G) Cell numbers 48 hr following thymidine block release.
(H) Western blot analysis of CYCLIN D1 levels following an ELA pulse.
(I) By FACS analysis, a larger proportion of shELA hESCs are positive for ANNEX
(J) Activated CASPASE 3 can be detected in shELA hESCs by immunofluoresce
(K) ELA can partially replace the ROCK inhibitor to prevent anoikis following sing
(L) ELA-treated hESCs are more resistant to g-irradiation compared to control hES
addition of ELA. Data are representative of three independent experiments.
(M) ELA-treated hESCs are more resistant to low levels of Actinomycin D treatme
hESCs are more sensitive but can be rescued by addition of ELA. Data are repre
See also Figure S6.
CeELA Protects Against Apoptosis and Prevents
Stress-Induced Cell Death
PI3K/AKT is equally recognized for its anti-apoptotic properties
in both normal and cancer cells (Fresno Vara et al., 2004). For
this reason, we hypothesized that ELA may prevent apoptosis
and thereby potentiate hESC growth. In support of this hypoth-
esis, a significantly higher proportion of shELA hESCs underwent
apoptosis, as marked by surface expression of ANNEXIN V (Fig-
ure 6I) and intracellular activated CASPASE 3 (Figure 6J and
Figure S6A). This suggests that endogenous ELA is required to
protect against apoptosis induced by routine in vitro culture con-
ditions, such as dissociation-induced cell death, also known as
anoikis (Watanabe et al., 2007). Indeed, shELA hESCs do not
survive single-cell dissociation in the absence of Y-27632, which
inhibits anoikis by inhibition of Rho-associated kinase (ROCK)
(Watanabe et al., 2007) (Figure 6K). Conversely, exogenous
ELA was able to increase survival following dissociation com-
pared to untreated hESCs, partially replacing Y-27632 (Fig-
ure 6K). Furthermore, shELA hESCs were twice as sensitive to
g-irradiation, which inflicts DNA damage, relative to control,
while ELA-treated hESCs were five times more resistant (Fig-
ure 6L) despite comparable numbers of DNA double-stranded
breaks marked by gH2AX (Figure S6B). These findings in hESCs
stand in contrast to the reported function of Ela in mESCs, where
instead it appears to promote apoptosis in response to DNA
damage (Li et al., 2015). Similar results were obtained when
hESCs were treated with nanomolar concentrations of Actino-
mycin D to inflict translational stress (Perry, 1962) (Figures 6M
and S6C). In both cases, shELA hESCs had increased levels of
activated CASPASE 3/7 (Figures S6B and S6D) and CASPASE
9 (Figure S6E), indicating increased activation of the intrinsic
apoptotic cascade (Gillies and Kuwana, 2014). This was due to
higher levels of BAX in the mitochondria and CYTOCHROME C
in the cytoplasm (Figure S6F), whichwas suppressed by addition
of exogenous ELA (Figure S6F). All together, our results indicate
that exogenous ELA acting through PI3K/AKT protects against
the intrinsic apoptosis pathway activated by a variety of cellular
stress, while hESCs depleted of ELA are highly sensitized to
stress.
ELA Primes Cells toward the Mesendoderm Lineage
We next sought to delineate the functions of ELA that are distinct
from INSULIN. Ela is known to be required for mesendoderm
differentiation during zebrafish embryogenesis (Chng et al.,
2013), a process that is highly dependent on Nodal/Tgfb. In
ELA-pulsed hESCs, we observed upregulation of several genes
related to the NODAL/TGFb pathway such as EOMES, GDF3,ck release.
IN V, which marks apoptotic cells.
nce, but not in control hESCs.
le-cell dissociation.
Cs. shELA hESCs are sensitized to g-irradiation, which can be rescued by the
nt, which induces transcriptional stress and p53-dependent cell death. shELA
sentative of six independent experiments.
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Figure 7. ELA Poises hESCs toward the
Mesendodermal Lineage
(A) ELA, but not INSULIN, activates pSMAD3, as
shown by western blot.
(B) ELA-mediated activation of pSMAD3 is insen-
sitive to PI3K inhibition by LY.
(C) Immunofluorescence of pSMAD3 in hESCs
pulsed with ELA.
(D) qPCR analysis of mesendoderm lineage genes
in hESCs grown in the presence of ELA or depleted
of ELA for 72 hr.
(E) FACs analysis of SSEA3 and TRA-1-60 levels on
hESCs grown in the presence of ELA for 72 hr.
(F) qPCR analysis of POU5F1 and NANOG in
hESCs grown in the presence of ELA for 72 hr.
(G) qPCR analysis of germ layer markers during
embroid body formation from hESCs grown in the
presence (pink) or absence (black) of exogenous
ELA prior to differentiation.
(H) SOX17 immunofluorescence of hESC-derived
definitive endoderm at Day 3 and Day 5 of differ-
entiation.
(I) Quantitation of SOX17-positive cells in (H).
See also Figure S7.FST, and TGFb1 (Figure 5B). Using GSEA analysis, we found that
transcripts that were upregulated by ELA were enriched for
genes upregulated during in vitro differentiation of hESCs
to definitive endoderm (DE) (Figure S7A; GEO: GSE25557).
Conversely, genes that were downregulated in shELA hESCs
are in fact upregulated during DE differentiation. Together, these
observations implicate ELA in DE lineage commitment, possibly
through modulation of NODAL/TGFb. Consistent with this possi-
bility, ELA-pulsed, but not INSULIN-pulsed, hESCs showed
increased levels and nuclear localization of carboxy phospho-
SMAD3 (Figures 7A and 7C), indicating activation of the
NODAL/TGFb pathway in a PI3K-independent manner (Fig-
ure 7B). After 72 hr, ELA-treated hESCs upregulated many
markers of the mesendoderm lineage, including BRA, EOMES,
and GATA4/6 (Figure 7D). The same set of differentiation
markers was downregulated in shELA hESCs (Figure 7D).
Despite these changes, ELA was not sufficient to commit hESCs444 Cell Stem Cell 17, 435–447, October 1, 2015 ª2015 Elsevier Inc.grown in mTSER1 toward the DE lineage,
as cells maintained an hESC morphology
(Figure 2G) and expressed normal, if not
higher, levels of the pluripotency markers
(Figures 7E and 7F). In addition, hESCs
treated with ELA were still able to give
rise to all three germ lineages during emb-
roid body differentiation (Figure 7G), indi-
cating that they remained pluripotent.
Hence, we propose that ELA, while not
sufficient to induce differentiation in the
absence of other cues such as BMP4
and ACTIVIN A, is required to maintain a
transcriptional profile that is permissive
for endoderm development. On the
contrary, shELA showed compromised
in vitro differentiation of SOX17+ definitive
endoderm, which could be fully rescuedby the addition of exogenous ELA in the culture medium (Figures
7H and 7I). We conclude that ELA, working through the NODAL/
TGFb pathway, is required for endoderm differentiation by keep-
ing hESCs primed toward the mesendoderm lineage.
DISCUSSION
ELA-Mediated Regulation of Embryonic Cell Growth and
Viability
Besides the well-studied NODAL/BMP, IGF/FGF, and WNT,
very few additional secreted factors with proven roles in plurip-
otency have been discovered in the last decade. Here we pre-
sent evidence that the extracellular peptide ELA plays an
important and specific role in self-renewing hESCs. ELA, like
INSULIN and IGFs, can activate the PI3K/AKT pathway and
is either the endogenous or an alternate activator of this crucial
pathway during early embryogenesis. Unlike FGF, which needs
to be added exogenously or secreted by feeder cells, ELA is
endogenously synthesized and secreted by hESCs in sufficient
quantities. Inhibition of ELA caused loss of cell proliferation,
apoptosis, and subsequent differentiation, suggesting that it
serves as an essential factor to counteract the high levels of
spontaneous apoptosis and differentiation inherent to hESC
cultures. In line with this, we note that the depletion of ELA
in hESCs grown as single cells is more detrimental than in
hESCs grown in colonies due to the higher rate of anoikis
following dissociation (Watanabe et al., 2007). Alternatively,
this might point to the extracellular activity of the peptide,
which may be more readily captured in a paracrine manner
by hESC colonies than it is by single cells. Also, we note that
while endogenous ELA is present in hESC-conditioned me-
dium in the nM range, our recombinant peptide, although
specific and bioactive, works in the mM range. This finding sug-
gests existence of possible post-translational modifications on
endogenous ELA that are required for its full potency, as is the
case for other peptide hormones such as GHRELIN (Kojima
et al., 1999).
ELA and INSULIN Are Functionally Distinct
INSULIN and IGFs are well known to stimulate pre-implanta-
tion embryonic growth in vitro, increasing the number of cells
in the inner cell mass of mouse embryos and protecting them
against apoptosis induced by oxidative stress (Kurzawa et al.,
2002; Markham and Kaye, 2003; Rappolee et al., 1992). While
ELA and INSULIN both activate PI3K/AKT in hESCs, their
functions are only partially complementary. ELA does not
bind to IGF or INSULIN receptors expressed abundantly in
hESCs (unpublished data), arguing against its role as an alter-
nate ligand of the INSULIN/IGF pathway. ELA and INSULIN
elicit different transcriptional responses in hESCs, pointing to
a different mode of action and set of downstream effectors.
Lastly, ELA’s ability to potentiate the NODAL/TGFb pathway
is unique and does not appear to be PI3K dependent. In
fact, canonical PI3K/AKT signaling activated by IGFs main-
tains self-renewal by restraining the prodifferentiation func-
tions of SMAD2/3 (Singh et al., 2012). In our hands, inhibition
of PI3K/AKT as a result of ELA depletion does not lead to
increased SMAD2/3-mediated differentiation (unpublished
data). Rather, ELA depletion impairs subsequent endoderm
differentiation, a process that is SMAD2/3 dependent. We
therefore propose a model whereby ELA, acting through an
alternate unknown receptor, promotes growth and survival
through PI3K/AKT while potentiating mesendoderm differenti-
ation through direct or indirect regulation of the NODAL/TGFb
pathway.
An Alternate Receptor for ELA Mediates Its Function in
hESCs
Our observation that recombinant ELA is rapidly taken up by
hESCs and that endogenous ELA can be found in the cyto-
plasm suggests that ELA signals via a dedicated receptor in
these cells. We do not favor the possibility that ELA behaves
as a self-penetrating peptide (Green and Loewenstein, 1988)
despite its very basic amino-acid makeup (Chng et al., 2013)
because its rapid cellular uptake is only observed in hESCs
and not in other tested cell types. As previously reportedCeand confirmed by us, APLNR is silent in hESCs. Furthermore,
APELIN13, the other endogenous ligand for APLNR, which
can activate PI3K/AKT in certain cell types (Tang et al.,
2007), has no effect on hESCs (data not shown). We therefore
believe that another cell-surface receptor mediates ELA’s
activity in hESCs.
Is Mouse Ela Lost In Translation?
A recent study reported a non-coding role of Elabela in pro-
moting p53-mediated DIA in embryonic stem cells of mouse
origin (mESCs). Intriguingly, this function was entirely depen-
dent on the 30 UTR of the murine Ela mRNA, which was pre-
dicted to form a secondary structure that interacts with the
p53-inhibitor hnRNPL protein (Li et al., 2015). This function
was shown to be entirely independent of the Ela ORF or its
peptide product. This finding draws the question of whether
human ELA also bears such a non-coding RNA function.
Several key differences exist between primate and other ver-
tebrates in regards to the structure of ELA’s 30 UTRs, which
is entirely encoded by its ultimate third exon (Figure S4L).
The 30 UTRs are of very different lengths: 2,113 bp in human
versus 573 bp in mouse. Moreover, the 30 UTR of human
ELA has acquired during primate evolution the insertion of
two anti-parallel 300 bp Alu repeats. Even without these Alu
repeats, the sequence conservation is poor between the two
species with an overall homology of less than 10%. Hence,
we propose that the secondary structures and protein-binding
properties of ELA and Ela mRNAs are likely to be species spe-
cific. Indeed, our results show that in hESCs, ELA mRNA pre-
vents rather than promotes DIA as reported by Huang and col-
leagues in mESCs. Consistent with the authors’ conclusions,
we found that Ela had no effects on mESC self-renewal and
growth under normal conditions. In fact, Ela knockout mice
have no overt pre-implantation defects (B.R., unpublished
data). These data point to a possible different role of Ela in
mouse compared to ELA in human with respect to pre-implan-
tation development and ESC maintenance. Nevertheless, we
do not rule out the idea that the human ELA mRNA may
have non-coding functions and we look forward to addressing
this question more in the future.
Taken together, our data suggest that mature ELA functions
as an endogenous hormonal peptide secreted by hESCs. It is
then taken up by hESCs in a paracrine manner and signals
through an unknown receptor to the PI3K/AKT pathway to sus-
tain survival and self-renewal of ESCs. As ELA is highly ex-
pressed in the human blastocyst, the stage from which hESCs
are derived, we speculate that it may play a similar protective
role in primate pre-implantation embryos. What endogenous
stress signal in the mammalian embryo ELA might protect
against is not entirely clear. Normoxia, replicative stress,
nutrient deprivation, and temperature are all potential stimuli
that could equally solicit the need for ELA during embryogen-
esis. Lastly, given the potent ability of ELA to activate PI3K/
AKT, promote growth, and prevent apoptosis, it is tempting
to speculate that cancer stem cells may also display a similar
dependence on ELA for tumor initiation and progression.
Thus, defining and studying the role of ELA in human
neoplasms seems a high priority given its attractiveness as a
potential therapeutic target.ll Stem Cell 17, 435–447, October 1, 2015 ª2015 Elsevier Inc. 445
EXPERIMENTAL PROCEDURES
Teratoma studies were undertaken with prior approval from Biological
Resource Centre under IACUC#110703.
Cell Culture and Assays
The SHEF4 cell line was used throughout and exhibits standard morphological
and surface marker characteristics of hESCs and a normal 46XY karyotype
(Inniss and Moore, 2006). Recombinant ELA or ELARR > GG was added at
2.5 mM (or 10 mg/ml) where indicated. Refer to the Supplemental Information
for details on assay protocols and reagents.
shRNA-Mediated ELA Knockdown
To generate stable inducible knockdown of ELA in hESCs, the sequence
GTGATTCTCGTGCCTCAAC targeting the 30 UTR of ELA was cloned into
pSUPERIOR (Oliogoengine) and nucleofected (LonzA) into SHEF4TetR5 hESCs
(Zafarana et al., 2009). Refer to the Supplemental Information for details.
ELISA
A custom sandwich ELISA assay was developed for detecting secreted ELA.
An in-house goat a C antibody (4 mg/ml) was used as the capture antibody
and a rabbit a C (0.8 mg/ml) was used as the detection antibody. Refer to
the Supplemental Information for details.
SILAC Cell Culture and Cell Lysis
SHEF4 hESCs were cultured in custom-made mTSER1 (Stem Cell Technol-
ogies) containing either stable medium isotopes of L-lysine-(2H4) (K4) and
L-arginine-(13C6) (R6) or heavy isotope L-lysine-(13C615N2) (K8) and L-argi-
nine-(13C615N4) (R10) for three passages to allow complete exchange of
isotopes. Cells were then starved in DMEM/F12 for 2 hr, which was followed
by a 10 min pulse with 5 mM of ELA or ELARR > GG. Lysates were subjected to
phospho-proteomic analysis. Refer to the Supplemental Information for
details.
Microarray Analysis
100 ng of purified RNA was used for cRNA generation and hybridization to the
Affymetrix HG-U133_Plus_2.0 platform according to the manufacturer’s pro-
tocol. Raw data were analyzed using GeneSpring GX (Agilent) to generate
normalized intensity readings. Refer to the Supplemental Information for
details.
Statistical Analysis
Unless otherwise indicated, all values were expressed as mean ± SEM. Com-
parison of means was performed using two-tailed Student’s unpaired t test
in Prism GraphPad, with significance levels indicated as follows: n.s. p >
0.05; *p% 0.05; **p% 0.01; ***p% 0.001.
ACCESSION NUMBERS
The accession number for the microarray data reported in this paper is GEO:
GSE71949.
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